Mirum Pharmaceuticals, Inc. reported total revenue of $128 million for the second quarter of 2025. This performance underscores the strength of its commercial programs, with notable outperformance from its international business and U.S. PFIC launch.
The company further increased its full-year 2025 revenue guidance to a range of $490 million to $510 million. This marks a second raise in guidance for the year, reflecting continued confidence in demand for its medicines.
Mirum also provided an update on its pipeline, stating that the VISTAS study of volixibat in PSC will complete enrollment in the third quarter of 2025, with topline data expected in the second quarter of next year. The net loss for Q2 2025 was $5.861 million, a significant improvement from $24.638 million in Q2 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.